Tornier N.V. (NASDAQ:TRNX) had its price target decreased by Piper Jaffray Cos. from $23.00 to $21.00 in a research report sent to investors on Wednesday morning, Analyst Ratings.Net reports. The firm currently has an overweight rating on the stock.
TRNX has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. cut their price target on shares of Tornier N.V. from $24.00 to $20.00 in a research note to investors on Wednesday. They now have an overweight rating on the stock. Separately, analysts at Summer Street downgraded shares of Tornier N.V. from a buy rating to a sell rating in a research note to investors on Wednesday. They now have a $14.00 price target on the stock, down previously from $26.00. Finally, analysts at BMO Capital Markets downgraded shares of Tornier N.V. from an outperform rating to a market perform rating in a research note to investors on Wednesday. They now have a $20.00 price target on the stock, down previously from $22.00. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $18.75.
Tornier N.V. (NASDAQ:TRNX) traded up 1.62% during mid-day trading on Wednesday, hitting $16.32. The stock had a trading volume of 100,357 shares. Tornier N.V. has a 52-week low of $14.53 and a 52-week high of $21.87. The stock’s 50-day moving average is $20.25 and its 200-day moving average is $18.38. The company’s market cap is $779.9 million.
Tornier N.V. (NASDAQ:TRNX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.18) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.04. The company had revenue of $66.70 million for the quarter, compared to the consensus estimate of $70.64 million. During the same quarter in the prior year, the company posted ($0.29) earnings per share. The company’s quarterly revenue was up 14.8% on a year-over-year basis. Analysts expect that Tornier N.V. will post $-0.57 EPS for the current fiscal year.
Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.